Erin Bastick, PharmD, RPh
How pharma reps impact physician prescribing
A new study led by The University of California researchers and published in JAMA reveals surprising findings.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetes
New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Cannabinoid-based drug pipeline shows promise
Cannabinoid-based drug pipeline shows promise
New treatment indications are under investigation for the use of cannabinoid-based drugs.
Cannabinoid-based drug pipeline grows: 4 ways to prepare
New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?
New diabetes medications help address linked diseases
Experts share updates on new diabetes medications, and provide an overview of what’s coming.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipeline
Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Statin prescribing varies in patients with diabetes
Wide variation exists in practice-level statin prescribing for patients with diabetes, according to a new study.
Insurer diabetes program engages consumers, lowers costs
Insurer diabetes program engages consumers, lowers costs
Anthem Blue Cross recently launched a year-long diabetes prevention program to educate, treat and support its qualified California members who are at risk of developing type 2 diabetes.
Drug pipeline developments: Alopecia areata and atopic dermatitis
Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Know these barriers to reduce type 2 diabetes costs
IMS Health study: Up to 15% of healthcare system costs avoidable and effective patient activation by multiple stakeholders is key to driving improvement.

Poll

View Results